ermectin – A Potent Weapon in the AntiCOVID-19 Armamentarium
Keywords:
SARS-CoV-2, antiviral drugs,, ivermectin, treatmentAbstract
The coronavirus disease 2019 (COVID-19) pandemic has become an earth-shattering menace afflicting the entire globe. With
no effective antiviral drugs in sight, the repurposing of many currently available drugs has been considered the mainstay of
treatment. One such drug is ivermectin (IVM), a Food and Drug Administration (FDA)-approved antiparasitic agent that has
been shown to exhibit antiviral activity against a broad range of viruses. Ivermectin proposes many potential effects to treat a
range of diseases, with its antimicrobial, antiviral and anticancer properties as a wonder drug. Several studies have reported
antiviral effects of IVM on RNA viruses such as Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan
equine encephalitis, chikungunya, Semliki Forest, Sindbis, Avian influenza A, porcine reproductive and respiratory syndrome,
human immunodeficiency virus type 1 and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recent studies
have suggested that IVM inhibits the replication of (SARS-CoV-2) in vitro, thus suggesting its potential for use against
COVID-19. In this review, we describe the mechanism of action, rationale, dosing protocols of IVM in the management and
prophylaxis of COVID-19 infection.
Downloads
Published
Issue
Section
License
All open access articles published in IJCP are distributed under the terms of the CC BY-NC 4.0 license (Creative Commons Attribution-Non-Commercial 4.0 International Public License). This license permits unrestricted use, distribution, and reproduction of the articles in any medium for non-commercial purposes, provided that: The original authorship is properly and fully attributed. The IJCP is cited as the original place of publication with correct citation details. If an original work is reproduced or disseminated in part or as a derivative work, this must be clearly indicated. No articles are reproduced for commercial use without prior consent from the IJCP. All licensing requests and permissions for commercial use will be managed by the Publisher.
